SVA (Sinovac Biotech) Total Liabilities: $1,673.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SVA Sinovac Biotech Ltd SVA
12 GF Score
Price $6.47
! 9 Warning Signs
View Full Analysis

What is Sinovac Biotech Total Liabilities?

Sinovac Biotech SVA 12 Total Liabilities is $1,673.9 Mil as of Jun. 2026. GuruFocus rates SVA with a GF Score™ of 12/100. The stock has 9 warning signs investors should review.

Sinovac Biotech's Total Liabilities for the quarter that ended in Jun. 2026 was $1,673.9 Mil.

Sinovac Biotech's quarterly Total Liabilities declined from Jun. 2025 ($5,643.59 Mil) to Dec. 2025 ($2,145.47 Mil) and declined from Dec. 2025 ($2,145.47 Mil) to Jun. 2026 ($1,673.88 Mil).

Sinovac Biotech's annual Total Liabilities increased from Dec. 2023 ($1,635.21 Mil) to Dec. 2024 ($2,043.85 Mil) and increased from Dec. 2024 ($2,043.85 Mil) to Dec. 2025 ($2,145.47 Mil).

Sinovac Biotech Total Liabilities Historical Data

* Premium members only.

The historical data trend for Sinovac Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinovac Biotech Total Liabilities Chart

Sinovac Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,872.17 1,401.91 1,635.21 2,043.85 2,145.47

Sinovac Biotech Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,389.94 2,043.85 5,643.59 2,145.47 1,673.88
SVA
12GF Score
Sinovac Biotech Ltd SVA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinovac Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sinovac Biotech's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1540.365+(274.124+0.023999999999944
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+330.96+0+0)
=2,145.5

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=8541.725-6396.252
=2,145.5

Sinovac Biotech's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1091.157+(240.752+0.025000000000091
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+341.95+0+0)
=1,673.9

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=8138.788-6464.904
=1,673.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $1,673.9 Mil mean?
Sinovac Biotech (SVA) has a Total Liabilities of $1,673.9 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sinovac Biotech and its competitors.
Is Sinovac Biotech's Total Liabilities too high?
Sinovac Biotech's current Total Liabilities is $1,673.9 Mil. Overall, Sinovac Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sinovac Biotech's Total Liabilities compare to INBX and HLVX?
Sinovac Biotech's Total Liabilities of $1,673.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sinovac Biotech and its competitors. Sinovac Biotech's current Total Liabilities is $1,673.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinovac Biotech stock overvalued right now?
Sinovac Biotech (SVA) has a current Total Liabilities of $1,673.9 Mil. The current Total Liabilities is $1,673.9 Mil. Sinovac Biotech's overall GF Score™ is 12/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Sinovac Biotech (SVA), the current Total Liabilities is $1,673.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sinovac Biotech Business Description

Address No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
12GF Score

Get the complete analysis for SVA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.47
Price